Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,115 matching trials from the live ClinicalTrials.gov search.
Not listed No phase listed Observational Accepts healthy volunteers

Overture Metabolomics Non-Selection Study

NCT04878991
Conditions
Infertility
Interventions
Overture Metabolomics Embryo Selection
Diagnostic Test
Lead sponsor
Overture Life
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Prenatal Disorder
Interventions
Standard Care, Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio
Conditions
Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria
Interventions
Autonomic Function Testing, Genetic Testing, Urine Testing, Blood laboratory Testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies, AR-42
Other · Drug
Lead sponsor
Amir Mortazavi
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes
Drug · Biological · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

Genetic Testing in Detection of Late-Onset Hearing Loss

NCT00511381
Conditions
Hearing Loss, Late-Onset Hearing Loss, Deafness
Interventions
No intervention
Genetic
Lead sponsor
Pediatrix
Other
Eligibility
Up to 14 Days
Enrollment
3,681 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
Topeka, Kansas • Dayton, Ohio • Oklahoma City, Oklahoma
Recruiting Not applicable Interventional Accepts healthy volunteers

Increasing Germline Genetic Testing for Patients With Cancer

NCT07307664
Conditions
Hereditary Pancreatic Cancer, Conditions or Focus of Study, Hereditary Breast Cancer, Hereditary Colorectal Cancer
Interventions
Implementation strategies
Behavioral
Lead sponsor
Josh Peterson
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Decatur, Georgia + 7 more
Completed Not applicable Interventional Accepts healthy volunteers

Acute Partner and Social Contact Referral: iKnow

NCT02467439
Conditions
Acute HIV Infection, HIV Seropositive, Sexually Transmitted Infections
Interventions
Notification cards
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Morbid Obesity
Interventions
Surgery
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2035
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
Interventions
Standard developed materials, Genetics Advisor Decision Aid
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
30 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Pharmacogenomic
Interventions
pharmacogenomic
Genetic
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Conditions
Rheumatic Disease
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Denver, Colorado • Bethesda, Maryland • Kettering, Ohio + 2 more
Conditions
Hereditary Disease, Genetic Predisposition to Disease
Interventions
Whole Genome Sequencing
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Months and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Craniometaphyseal Dysplasia
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Colon Cancer, Endometrial Cancer
Interventions
Genetic testing
Other
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

NCT03326713
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC)
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older · Female only
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

NCT04254133
Conditions
Prostate Carcinoma
Interventions
Questionnaire, Biospecimen Collection, Genetic Testing, Genetic Counseling, Laboratory Biomarker Analysis
Behavioral · Procedure · Diagnostic Test + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
35 Years to 89 Years · Male only
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Completed No phase listed Observational

Genetic Linkage Studies of Stuttering

NCT00001604
Conditions
Stuttering
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
6 Years and older
Enrollment
3,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
Interventions
NSR IDE-MRI: Research pulse sequences
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Cherubism
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
1
States / cities
Farmington, Connecticut